Status | Study |
Recruiting |
Study Name: BMT Abatacept for Non-Malignant Diseases Condition: Hurler Syndrome Fanconi Anemia Glanzmann Thrombasthenia Date: 2013-07-24 Interventions: Drug: Abatacept All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis |
Recruiting |
Study Name: Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders Condition: Chronic Kidney Disease Acute Myeloid Leukemia (AML) Acute Date: 2012-12-17 Interventions: Procedure: Haploidentical Bone Marrow/Kidney Combined bone marrow and kidney transplantation using a hap |
Recruiting |
Study Name: Human Placental-Derived Stem Cell Transplantation Condition: Mucopolysaccharidosis I Mucopolysaccharidosis VI Adrenoleu Date: 2012-04-25 Interventions: Drug: Human Placental Derived Stem Cell Infusions of thawed HPDSC to be given following UCB infusion. |
Active, not recruiting |
Study Name: Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Condition: Accelerated Phase Chronic Myelogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remissi Date: 2012-02-06 Interventions: Drug: fludarabine phosphate Gi |
Recruiting |
Study Name: Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia Condition: Diamond Blackfan Anemia Date: 2011-10-31 Interventions: Drug: Sotatercept |
Suspended |
Study Name: Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies Condition: Anemia, Sickle Cell Complex and Transfusion-dependent Hemoglobinopathies Date: 2011-08-16 Interventions: Biological: Enriched Hematopoetic Stem Cell Infusion Enriched Hematopoetic Stem Cell Infusion |
Active, not recruiting |
Study Name: Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia Condition: Diamond Blackfan Anemia Blackfan Diamond Date: 2011-05-20 Interventions: Drug: leucine Dosage of leucine will be dependent on body |
Suspended |
Study Name: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation Condition: Thalassemia Sickle Cell Disease Glanzmann Thrombasthenia Date: 2010-09-15 Interventions: Drug: Alefacept 0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacep |
Terminated |
Study Name: Multi-Center Study of Iron Overload: Pilot Study Condition: Sickle Cell Disease Thalassemia Diam Date: 2010-04-30 |
Completed |
Study Name: A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity Condition: Transfusional Iron Overload Date: 2010-01-05 Interventions: Drug: ICL670 |